FX.co ★ Tourmaline Bio Announces Pricing Of 4.61 Mln Public Offering

Tourmaline Bio, Inc., a clinical biotechnology firm, has declared on Thursday that plans for a public offering of 4.61 million common shares have been set in motion. Each share will be priced at $32.50. In conjunction with this, underwriters have received the green light to acquire an additional 692,307 common stocks within a 30-day time frame if they choose to do so. The firm anticipates that the gross proceeds from this initiative will mount to $150 million. The tentative closing date for this offering is slated for January 29. As far as pre-market activities are concerned, the company's shares are currently valued at $35.30 in the Nasdaq, marking a 1.97% decline.